NeoGenomics outlines $793M-$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction
Source: SeekingAlpha
2026-02-17 12:56:17 ET
More on NeoGenomics
- NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
- NeoGenomics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- NeoGenomics: Distribution Moat In Community Oncology
- NeoGenomics Non-GAAP EPS of $0.06 beats by $0.02, revenue of $190.17M beats by $1.89M
- NeoGenomics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction
NeoGenomics Inc.
NASDAQ: NEO
NEO Trading
-1.8% G/L:
$8.725 Last:
340,070 Volume:
$8.88 Open:
NEO Latest News
February 25, 2026 07:05:00 am
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NEO Stock Data
$1,500,898,492
126,282,494
0.16%
88
N/A
Medical Diagnostics & Screening
Healthcare
US
Fort Myers
